Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

被引：14
|
作者：
Loriot, Yohann [1 ]
Powles, Thomas [2 ]
Duran, Climent Miguel Angel [3 ]
Sridhar, Srikala S. [4 ]
Bellmunt, Joaquim [5 ]
Petrylak, Daniel Peter [6 ]
Wang Jing [7 ]
Costa, Nuno Matos [8 ]
Laliberte, Robert J. [7 ]
Di Pietro, Alessandra [9 ]
Grivas, Petros [10 ]
Sternberg, Cora N. [11 ]
机构：
[1] Univ Paris Saclay, Gustave Roussy, INSERM, U981, Villejuif, France
[2] Queen Mary Univ London, St Bartholomews Hosp, Barts Canc Inst, Expt Canc Med Ctr, London, England
[3] Inst Valenciano Oncol, Valencia, Spain
[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Harvard Med Sch, Dept Med Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
[6] Yale Canc Ctr, New Haven, CT USA
[7] Pfizer Inc, Cambridge, MA USA
[8] Pfizer, Porto Salvo, Portugal
[9] Pfizer SRL, Milan, Italy
[10] Univ Washington, Dept Med, Div Oncol, Clin Res Div,Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[11] New York Presbyterian Hosp, Weill Cornell Med, Hematol Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
438
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.
    Tsuchiya, Norihiko
    Yamamoto, Yoshiaki
    Uemura, Hirotsugu
    Kanayama, Hiro-Omi
    Eto, Masatoshi
    Miyake, Hideaki
    Powles, Thomas
    Yoshida, Mizuki
    Koide, Yuichiro
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Tomita, Yoshikiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [2] Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
    Grivas, P.
    Park, S. H.
    Voog, E.
    Caserta, C.
    Perez Valderrama, B.
    Gurney, H.
    Kalofonos, H.
    Radulovic, S.
    Demey, W.
    Ullen, A.
    Loriot, Y.
    Sridhar, S. S.
    Tsuchiya, N.
    Kopyltsov, E.
    Gupta, S.
    Huang, B.
    Costa, N.
    Blake-Haskins, J. A.
    di Pietro, A.
    Powles, T. B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S555 - S556
  • [3] Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis.
    Eto, Masatoshi
    Lee, Jae-Lyun
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, T. W.
    Desai, Chirag Jyotiker
    Di Pietro, Alessandra
    Wang, Jing
    Laliberte, Robert J.
    Gao, Seasea
    Gurney, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
    Grivas, Petros
    Park, Se Hoon
    Voog, Eric
    Kopyltsov, Evgeny
    Gurney, Howard
    Muniz, David Queiroz Borges
    Rolland, Frederic
    Als, Anne Birgitte
    Valderrama, Begona P.
    Wang, Jing
    Costa, Nuno Matos
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Powles, Thomas
    Bellmunt, Joaquim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Maintenance avelumab plus best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
    Powles, Thomas
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Valderrama, B. P.
    Gurney, Howard
    Kalofonos, Haralabos
    Radulovic, Sinisa
    Demey, Wim
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Tsuchiya, Norihiko
    Kopyltsov, Evgeny
    Sternberg, Cora N.
    Bellmunt, Joaquim
    Aragon-Ching, Jeanny B.
    Petrylak, Daniel Peter
    di Pietro, Alessandra
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (18)
  • [6] Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
    Powles, T. B.
    Kopyltsov, E.
    Su, P-J.
    Parnis, F. X.
    Park, S. H.
    Yamamoto, Y.
    Fong, P. C.
    Tournigand, C.
    Duran, M. A. Climent
    Bamias, A.
    Caserta, C.
    Chang, J.
    Yan, E.
    di Pietro, A.
    Wang, J.
    Grivas, P.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S578 - S579
  • [7] Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
    Yoshihiko Tomita
    Yoshiaki Yamamoto
    Norihiko Tsuchiya
    Hiroomi Kanayama
    Masatoshi Eto
    Hideaki Miyake
    Thomas Powles
    Mizuki Yoshida
    Yuichiro Koide
    Yoshiko Umeyama
    Alessandra di Pietro
    Hirotsugu Uemura
    [J]. International Journal of Clinical Oncology, 2022, 27 : 383 - 395
  • [8] Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
    Tomita, Yoshihiko
    Yamamoto, Yoshiaki
    Tsuchiya, Norihiko
    Kanayama, Hiroomi
    Eto, Masatoshi
    Miyake, Hideaki
    Powles, Thomas
    Yoshida, Mizuki
    Koide, Yuichiro
    Umeyama, Yoshiko
    di Pietro, Alessandra
    Uemura, Hirotsugu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 383 - 395
  • [9] Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis
    Lee, Jae-Lyun
    Desai, Chirag
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, Timothy Tim Wai
    Gurney, Howard
    Gao, Seasea
    Wang, Jing
    Sandner, Robin
    di Pietro, Alessandra
    Eto, Masatoshi
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 256.e17 - 256.e25
  • [10] Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
    Powles, T. B.
    Loriot, Y.
    Bellmunt, J.
    Sternberg, C. N.
    Sridhar, S.
    Petrylak, D. P.
    Tambaro, R.
    Dourthe, L. M.
    Alvarez-Fernandez, C.
    Aarts, M.
    Mu, X. J.
    Ching, K. A.
    Pu, J.
    Roychoudhury, S.
    Davis, C. B.
    di Pietro, A.
    Grivas, P.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S552 - S553
12345